Mike Hennessy Jr.

The April issue of Pharmaceutical Commerce examines the accelerated activity—and many ever-expanding layers—of temperature-sensitive transport in pharma.

Our February issue is highlighted by an examination of the latest trends and strategies from the perspective of third-party logistics providers, and introduces new expert commentary covering a pair of pivotal realms in the pharma supply chain journey.

Our December analysis of the twists and turns in the Drug Supply Chain Security Act is a timely one, as the FDA recently again pushed back the deadline for complying with new mandates on tracking and tracing drugs at the package level.

Headlining our October issue of Pharmaceutical Commerce is a look inside an emerging key component of cold chain transport and management—ensuring the safety and control of novel injectable drugs through to their "last mile."

The August issue of Pharmaceutical Commerce explores an area of the pharma business engine that can often fall under the radar: inventory management and optimization.

The June issue of Pharmaceutical Commerce is headlined by a look at the influence of artificial intelligence and real-world evidence/real-world data on patient behavior and ultimately, the many complex factors that go into medicine adherence.

An exploration of the new demands in cold-chain visibility and sustainability—and the resulting tech-driven efforts to address them—leads off our coverage in this month's issue.

The February issue is centered around third-party logistics providers, including new dynamics and future trends that affect this key supply chain link.

December's installment reinforces the publication's commitment to covering the latest updates on patient support.

October's issue continues its dedicated coverage surrounding the cold chain.

The August issue varies in subject matters, from the outlook for drug wholesaling to the value of a user-centric approach for drug adherence.

The publication's June installment features a plethora of coverage, ranging from the learning curve in digital adoption to an overview of the CVD market.